EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Comparative Adverse-Event Risk in Placebo-Controlled Phase I Trials: A Systematic Review and Meta-Analysis in Healthy Korean Participants

Ju-won Heo, Hye-lin Lee, Seung-Hun You, A-Young Yang, Joungeun Sheen, Hyounggyoon Yoo, Wonsuk Shin, Yil-Seob Lee

Pharmaceuticals · 12.11.2026 · 19 (11) · 1790

DOI: 10.3390/ph19111790 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmaceuticals, online erschienen am 12.11.2026. Verfasst von Ju-won Heo und 7 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Adverse events in phase I trials may reflect treatment, background symptoms, or study procedures. We compared investigational treatment with placebo in healthy Korean participants.

Methods

We searched PubMed, Embase, Scopus, the Korea Citation Index, the Research Information Sharing Service, and Google Scholar through 30 April 2026 (PROSPERO: CRD420261426647). Outcomes were any treatment-emergent adverse event or adverse event (any TEAE/AE) and adverse drug reaction or treatment-related AE (ADR/related AE). The prespecified inverse-variance random-effects analysis used 0.5 continuity correction, Paule–Mandel variance estimation, and modified Hartung–Knapp confidence intervals (CIs). Post hoc analyses used treatment-arm correction, Mantel–Haenszel pooling without correction, and a Poisson mixed model.

Results

Forty-one studies were included. Any TEAE/AE was reported in 323/929 active-treatment and 66/267 placebo recipients; ADRs/related AEs occurred in 230/960 and 53/282. Prespecified risk ratios were 1.108 (95% CI 0.885–1.388) and 0.971 (0.764–1.234). Continuity-corrected inverse-variance analyses showed no significant difference. Mantel–Haenszel and Poisson estimates for any TEAE/AE were 1.393 (1.122–1.728) and 1.396 (1.070–1.820); ADR/related AE results were borderline and method-dependent. A highly imprecise gastrointestinal signal rested on one placebo event. Most risk-of-bias assessments raised some concerns.

Conclusions

This was not an equivalence or non-inferiority analysis. Comparative estimates were sensitive to sparse-data methods, and clinically important increases in risk cannot be excluded. Concurrent controls and complete arm-specific reporting remain essential for interpreting early safety signals.

Zitieren

APA

Heo, J., Lee, H., You, S., Yang, A., Sheen, J., Yoo, H., Shin, W., & Lee, Y. (2026). Comparative Adverse-Event Risk in Placebo-Controlled Phase I Trials: A Systematic Review and Meta-Analysis in Healthy Korean Participants. Pharmaceuticals, 19(11), 1790. https://doi.org/10.3390/ph19111790

Vancouver

Heo J, Lee H, You S, Yang A, Sheen J, Yoo H, et al. Comparative Adverse-Event Risk in Placebo-Controlled Phase I Trials: A Systematic Review and Meta-Analysis in Healthy Korean Participants. Pharmaceuticals. 2026;19(11):1790. doi:10.3390/ph19111790

BibTeX
@article{Heo2026,
  author = {Heo, Ju-won and Lee, Hye-lin and You, Seung-Hun and Yang, A-Young and Sheen, Joungeun and Yoo, Hyounggyoon and Shin, Wonsuk and Lee, Yil-Seob},
  title = {Comparative Adverse-Event Risk in Placebo-Controlled Phase I Trials: A Systematic Review and Meta-Analysis in Healthy Korean Participants},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1790},
  doi = {10.3390/ph19111790}
}
Kostenlos starten →